Skip to content

Samm50 Downregulation-Driven Mitochondrial Dysfunction Triggers Ferroptosis and Contributes to Ketamine-Induced Neurotoxicity and Cognitive Impairment.

Yuanlong Li, Xiangyun Dai, Junmei Hu, Yunke Zuo, Yi Li, Zhongjie Sun, Zhilin Jia, Xia Wang, Peipei Wang, Linchuan Liao

Neuropharmacology September 18, 2026 DOI: 10.1016/j.neuropharm.2026.111192 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study using a mouse model and cell line Peer reviewed
Population Mice with ketamine-induced cognitive impairment and HT22 hippocampal neuronal cells
Interventions Ketamine Fer-1 deferoxamine (DFO) MitoQ Samm50 overexpression
Topics Ketamine Esketamine
Keywords Cognitive impairment Ferroptosis Hippocampal neurotoxicity Mitochondrial dysfunction Samm50
Key points The authors propose that ketamine first downregulates Samm50, causing mitochondrial dysfunction (energy failure and oxidative stress), which then triggers ferroptosis via iron accumulation and suppression of GPX4/SLC7A11. Samm50 overexpression restored mitochondrial function and upregulated GPX4 and SLC7A11, ameliorating ferroptosis, which the authors present as evidence that Samm50 is a critical upstream link and a potential therapeutic target.

Abstract

Ketamine abuse is associated with persistent cognitive deficits and neurotoxicity, though the underlying mechanisms remain incompletely understood. While mitochondrial dysfunction and ferroptosis have been separately implicated, their causal relationship and the key molecular link in ketamine-induced hippocampal damage are unclear. Using a mouse model of ketamine-induced cognitive impairment and an HT22 hippocampal neuronal cell line, we found that ketamine significantly downregulated Samm50, a key protein maintaining mitochondrial outer membrane integrity, in both the hippocampus and HT22 cells. This downregulation was accompanied by reduced mitochondrial membrane potential (MMP) and ATP levels, and elevated reactive oxygen species (ROS). Concurrently, ketamine upregulated transferrin receptor TFR1, led to Fe2+/Fe3+ accumulation, increased malondialdehyde (MDA) and lipid peroxidation (LPO), and decreased the ferroptosis regulators GPX4 and SLC7A11. In vitro, ferroptosis inhibitors Fer-1 and deferoxamine (DFO) reversed ketamine-induced cell death, Fe2+ overload, LPO, and MMP loss, but Fer-1 failed to restore ATP or Samm50 expression. MitoQ rescued ATP, MMP, and ROS. Strikingly, Samm50 overexpression not only restored mitochondrial function (ATP, MMP, ROS) but also upregulated GPX4 and SLC7A11, thereby ameliorating ferroptosis. Collectively, ketamine induces hippocampal neurotoxicity and cognitive impairment via a two-step mechanism: it first downregulates Samm50, leading to primary mitochondrial dysfunction (energy failure and oxidative stress); this mitochondrial impairment then triggers ferroptosis through iron accumulation and suppression of GPX4/SLC7A11. Samm50 downregulation serves as a critical upstream event linking mitochondrial dysfunction to ferroptosis, representing a novel therapeutic target for ketamine-induced neuropsychiatric toxicity.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Ketamine downregulated Samm50, causing mitochondrial dysfunction that triggered ferroptosis via iron accumulation and suppression of GPX4/SLC7A11, contributing to hippocampal neurotoxicity and cognitive impairment.

    Synthesized

Comparable studies

Other preclinical and animal studies on ketamine, most cited first.

Citations in the library

Explore topics